Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria
British Journal of Clinical Pharmacology2025cited by 6position: middledoi
Phase 3 randomized <scp>COMMODORE</scp> 2 trial: Crovalimab versus eculizumab in patients with <scp>paroxysmal nocturnal hemoglobinuria</scp> naive to complement inhibition
American Journal of Hematology2024cited by 38position: middledoi